1. Home
  2. ICCM vs AEMD Comparison

ICCM vs AEMD Comparison

Compare ICCM & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

N/A

Current Price

$0.72

Market Cap

3.6M

Sector

N/A

ML Signal

N/A

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

N/A

Current Price

$5.30

Market Cap

3.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ICCM
AEMD
Founded
2006
1984
Country
Israel
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.9M
IPO Year
2013
2008

Fundamental Metrics

Financial Performance
Metric
ICCM
AEMD
Price
$0.72
$5.30
Analyst Decision
Strong Buy
Hold
Analyst Count
3
2
Target Price
★ $22.67
$13.25
AVG Volume (30 Days)
★ 110.0K
42.8K
Earning Date
11-18-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$27.11
N/A
Revenue Next Year
$104.97
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.13
$0.53
52 Week High
$9.54
$25.20

Technical Indicators

Market Signals
Indicator
ICCM
AEMD
Relative Strength Index (RSI) 29.69 48.11
Support Level $0.65 $4.86
Resistance Level $0.74 $6.09
Average True Range (ATR) 0.10 0.39
MACD 0.02 -0.03
Stochastic Oscillator 18.43 22.33

Price Performance

Historical Comparison
ICCM
AEMD

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.

Share on Social Networks: